Digene Reaches Investors And Consumers With Ads; OTC Index Up 4.4%

Digene's direct-to-consumer advertising campaign persuaded consumers and investors that its HPV Test is the standard of care for cervical cancer screening, driving the firm's stock up 34% to close the first quarter at $39.10